CASM, CRWE, MANH, NYMX - PennyOtcStock.com Stock Highlights! CAS Medical Systems, Crown Equity Holdings, Manhattan Associates, N
CPWR, FCBC, CRWE, NYMX - CRWEFinance.com Stock News! Compuware Corporation, First Community Bancshares, Crown Equity Holdings, N
(ILMN, NYMX, CRWE, AUDC) StockBlizzard.com Stock Market Report
NYMX, NHPR, CLNO, GWR, TRH, TEL - PennyToBuck.com Stock Report!
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) specializes in the research and development of novel drugs and diagnostic products for the aging population. Nymox Pharmaceutical’s lead drug candidate is NX-1207, a proprietary treatment for enlarged prostate or benign prostatic hyperplasia (BPH). NX-1207 is currently in Phase 3 trials in the United States.
NYMX, NHPR, CLNO, ROVI, XRAY, FMCN, - CRWESelect.com Stock Report! Nymox Pharmaceutical Corporation, National Health Partners
NYMX, NHPR, CLNO, TRGT, MICC, SINA - Stock Update From DoubleInStocks.com (Informative Video On NYMOX Included)
Source CRWESelect : NYMX, ENZ, KNDI, AMRN, - Nymox Pharmaceutical, Enzo Biochem, Kandi Technologies and Amarin Corporation Stock
Stock Highlight for GRHU & NYMX from DrStockPick.com
Recordati and Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced recently the signing of a European licensing agreement for the development and commercialization of NX-1207, Nymox's Phase III investigational drug currently in clinical development in the U.S. for the treatment of benign prostatic hyperplasia (BPH).
(WRES, GPRE, AVOT, NYMX) Stock Watch From PennyOmega.com
Businesses Jumping Through Hoops - IMAX, MSLP, NYMX, DRCO - DoubleInStocks.com
MusclePharm(R) Corporation (OTCBB: MSLP) , one of the fastest growing nutritional supplement companies in the United States with a proprietary formulation used in eight performance products, recently announced Bodybuilding.com selected MusclePharm as the Supplement Company of the Month for October.